Innoviva, Inc. (INVA)
INVA moved a median of +0.10% 30 minutes after news, and +0.02% by the close. How INVA actually reacts to news — the realized, point-in-time move the market made, measured across 166 labeled events over the last three years with zero look-ahead.
INVA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 165 |
| 30-min | +0.10% | 54% | 166 |
| 60-min | -0.10% | 48% | 166 |
| to close | +0.02% | 50% | 166 |
| Middle 50% of INVA reactions | -0.64% to +0.80% |
|---|---|
| Median reaction (30-min) | +0.10% |
| Measured reactions | 166 |
Half of all Innoviva, Inc. news events land between -0.64% and +0.80% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How INVA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 18 | +0.07% | 50% | -0.17% |
| Analyst downgrades | 13 | 0.00% | 39% | +0.20% |
| Coverage initiations | 22 | +0.15% | 59% | -0.51% |
| Rating reiterations | 19 | +1.04% | 63% | +0.40% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how INVA ranks against every other measured name →
That’s how INVA usually reacts — get an email when it moves on news →Email me when INVA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to INVA's baseline. Nothing else.
Recent INVA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Innoviva to Participate in Upcoming Investor Conferences | Press release | Business Wire | +0.68% | +0.38% | |
| Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award | Press release | Business Wire | +0.05% | +0.58% | |
| Form 10-Q Innoviva, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.18% | -0.10% | |
| Form 8-K Innoviva, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | -0.10% | |
| Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress | Press release | Business Wire | -1.18% | -0.10% | |
| Nortiva Bio Launches to Develop Long-Acting Oral Medicines | Press release | Business Wire | -0.74% | -2.00% | |
| Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets | Press release | Business Wire | +0.17% | +0.04% | |
| Innoviva to Participate in Upcoming Investor Conferences | Press release | Business Wire | -0.02% | +1.03% | |
| Form 8-K Innoviva, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -0.37% | |
| Form 10-Q Innoviva, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.63% | -4.80% | |
| Form 8-K Innoviva, Inc. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -1.63% | -4.80% | |
| Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress | Press release | Business Wire | -1.63% | -4.80% | |
| Form 8-K Innoviva, Inc. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +0.33% | -1.65% | |
| Form S-8 Innoviva, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.33% | -1.65% | |
| Form 10-K/A Innoviva, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.55% | +0.88% | |
| Form DEF 14A Innoviva, Inc. For: Mar 24 | SEC filing · Form DEF | SEC EDGAR | +0.48% | +2.31% | |
| Form 10-K Innoviva, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.97% | -5.84% | |
| Form 8-K Innoviva, Inc. For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -2.97% | -5.84% | |
| Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress | Press release | Business Wire | -2.97% | -5.84% | |
| Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | Business Wire | -0.25% | -0.71% | |
| U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents | Press release | Business Wire | +0.07% | -2.38% | |
| Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea | Press release | Business Wire | -0.76% | -1.57% | |
| Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference | Press release | Business Wire | +1.09% | +1.07% | |
| Form 10-Q Innoviva, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.01% | +3.68% | |
| Form 8-K Innoviva, Inc. For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -1.01% | +3.68% | |
| Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress | Press release | Business Wire | -1.01% | +3.68% | |
| Antheia Appoints Eric d'Esparbes as Chief Financial Officer | Press release | PR Newswire | +0.00% | +1.28% | |
| Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025 | Press release | Business Wire | -0.17% | -0.58% | |
| Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025 | Press release | Business Wire | -0.86% | -0.86% | |
| Innoviva to Participate in Upcoming Investor Conferences | Press release | Business Wire | -0.15% | +0.25% | |
| Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award | Press release | Business Wire | -0.59% | +2.13% | |
| Form 10-Q Innoviva, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.08% | +1.09% | |
| Form 8-K Innoviva, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +2.08% | +1.09% | |
| Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress | Press release | Business Wire | +2.08% | +1.09% | |
| FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | Press release | Business Wire | +0.37% | +0.05% | |
| Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults | Press release | Business Wire | +0.12% | -0.55% | |
| Innoviva to Participate in Upcoming Investor Conferences | Press release | Business Wire | +0.27% | +2.28% | |
| Form 8-K Innoviva, Inc. For: May 19 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | -0.53% | |
| ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections | Press release | Business Wire | +0.16% | +0.91% | |
| Form 10-Q Innoviva, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.80% | -0.96% | |
| Form 8-K Innoviva, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.80% | -0.96% | |
| Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress | Press release | Business Wire | -0.80% | -0.96% | |
| Form ARS Innoviva, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.18% | +1.88% | |
| Form DEF 14A Innoviva, Inc. For: May 19 | SEC filing · Form DEF | SEC EDGAR | +0.18% | +1.88% | |
| Form DEFA14A Innoviva, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.18% | +1.88% | |
| Form 10-K/A Innoviva, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.06% | +0.52% | |
| Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference | Press release | Business Wire | +0.57% | +0.40% | |
| Form 10-K Innoviva, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.61% | -2.72% | |
| Form 8-K Innoviva, Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +1.61% | -2.72% | |
| Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress | Press release | Business Wire | +1.61% | -2.72% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the INVA section they belong to.
Where else INVA is measured.
INVA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | 166 | -0.48% | 44% |
| CymaBay Therapeutics Inc. (CBAY) | 166 | +0.02% | 52% |
| MediWound Ltd. - Ordinary Shares (MDWD) | 166 | +0.11% | 53% |
| XBiotech Inc. (XBIT) | 165 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Innoviva, Inc.'s median reaction calculated?
Every labeled INVA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 166 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of INVA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does INVA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.